Our results are in line with some previous reports showing that downregulation of WT1 by using antisense oligonucleotides led to inhibition of cellular proliferation of K562 and fresh leukemia cells from AML and CML patients [39]. This evidence concerns the gene WT1 and chronic myelogenous leukemia, BCR-ABL1 positive.